Meropenem in cystic fibrosis patients infected with resistant Pseudomonas aeruginosa or Burkholderia cepacia and with hypersensitivity to β-lactam antibiotics
Authors:
Open Access
- 1 October 1996
- journal article
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 2 (2) , 91-98
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Allergic Reactions to Parenteral Beta-lactam Antibiotics in Patients With Cystic FibrosisChest, 1994
- Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF CenterAPMIS, 1994
- Pseudomonas cepacia—more than a harmless commensal?The Lancet, 1992
- Retrospective Clinical Study of Hypersensitivity Reactions to Aztreonam and Six Other β-Lactam Antibiotics in Cystic Fibrosis Patients Receiving Multiple Treatment CoursesClinical Infectious Diseases, 1991
- Safety of Aztreonam in Patients with Cystic Fibrosis and Allergy to β-Lactam AntibioticsClinical Infectious Diseases, 1991
- In vitro activity and beta-lactamase stability of a new carbapenem, SM-7338Antimicrobial Agents and Chemotherapy, 1989
- Comparative activity of meropenem against Pseudomonas aeruginosa strains with well-characterized resistance mechanismsJournal of Antimicrobial Chemotherapy, 1989
- Management of Pseudomonas Aeruginosa Lung Infection in Danish Cystic Fibrosis PatientsActa Paediatrica, 1987
- Allergy to semisynthetic penicillins in cystic fibrosisThe Journal of Pediatrics, 1984
- Chemotherapy of Chronic Infections with Mucoid Pseudomonas Aeruginosa in Lower Airways of Patients with Cystic FibrosisScandinavian Journal of Infectious Diseases, 1979